Share Performance

Stock Quote & Chart

Stock Quote | Stock Chart | Investment Calculator | Historical Lookup
Recent Newsmore >
08/07/17
Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
Expects top-line data from LEAP 1 CABP Phase 3 trial in September 2017 and from LEAP 2 CABP Phase 3 trial in the first quarter 2018 DUBLIN, Ireland, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its ... 
08/02/17
Nabriva Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Gary Sender, Chief Financial Officer of Nabriva Therapeutics plc, will provide a company overview and business update at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16... 
07/11/17
Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer
Further Strengthens Management Team of Industry Veterans to Support Commercialization of Potential New Antibiotic for Community-Acquired Bacterial Pneumonia DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Francesco Maria Lav...